Hybio Pharmaceutical Co., Ltd. (SZSE:300199) agreed to acquire remaining 40% stake in Shenzhen Huaxiang Zhiyuan Biotechnology Center (Limited Partnership) and Hybio Biotechnology (Dali) Co., Ltd. from Zhou Zhenke for CNY 0.15 million on April 27, 2023. Transaction has been approved by Hybio Pharmaceutical's board. For the period March 31, 2023, Shenzhen Huaxiang Zhiyuan had CNY 3.43953562 million of total assets and CNY 3.3942402 million of Net assets.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.18 CNY | -1.22% | +2.44% | -10.31% |
May. 29 | 3SBIO Unit to Cooperate on Development, Sale of Weight Management Injection | MT |
May. 29 | Hybio Pharmaceutical Grants Commercial Rights of Weight Loss Drug to Sansheng Mandi Pharmaceutical | MT |
1st Jan change | Capi. | |
---|---|---|
-10.31% | 1.49B | |
+15.91% | 41.97B | |
+23.56% | 22.34B | |
+18.48% | 15.25B | |
+16.12% | 14B | |
+45.12% | 12.06B | |
-9.48% | 6.8B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+14.18% | 5.49B |
- Stock Market
- Equities
- 300199 Stock
- News Hybio Pharmaceutical Co., Ltd.
- Shenzhen Huaxiang Zhiyuan Biotechnology Center (Limited Partnership) and Hybio Biotechnology Co., Ltd. from Zhou Zhenke for CNY 0.15 million.